$TNXP
Tonix Pharmaceuticals Holding Corp. Stock $tnxp

$tnxp Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000199937124010281 Filed on August 16, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q4
Revenue	$2.822M	$2.208M	$3.779M
YoY Change	-29.26%
Cost Of Revenue	$1.555M	$3.367M	$2.367M
YoY Change	-34.5%
Gross Profit	$1.267M	-$1.159M	$1.412M
YoY Change	-21.55%
Gross Profit Margin	44.9%	-52.49%	37.36%
Selling, General & Admin	$7.707M	$7.502M	$11.62M
YoY Change	-11.54%	6.77%	44.29%
% of Gross Profit	608.29%		823.02%
Research & Development	$9.114M	$9.698M	$17.12M
YoY Change	-56.7%	-55.87%	-30.62%
% of Gross Profit	719.34%		1212.46%
Depreciation & Amortization	$510.0K	$1.205M	$1.261M
YoY Change	-58.2%	33.89%	50.84%
% of Gross Profit	40.25%		89.31%
Operating Expenses	$16.82M	$17.20M	$28.74M
YoY Change	-43.48%	-21.73%	-12.18%
Operating Profit	-$15.55M	-$77.32M	-$27.33M
YoY Change	-44.74%	166.59%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$327.0K	-$605.0K	$7.000K
YoY Change	-290.12%	-193.65%
Pretax Income	-$14.21M	-$78.78M	-$27.32M
YoY Change	-49.2%	177.81%	-13.76%
Income Tax
% Of Pretax Income
Net Earnings	-$14.21M	-$78.78M	-$27.32M
YoY Change	-49.19%	177.81%	-19.84%
Net Earnings / Revenue	-503.65%	-3567.75%	-723.0%
Basic Earnings Per Share	-$0.23	-$19.28
Diluted Earnings Per Share	-$0.23	-$19.28	-$0.86
COMMON SHARES
Basic Shares Outstanding	22.00M shares	84.49M shares	23.85M shares
Diluted Shares Outstanding	62.12M shares	4.085M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.23M	$4.156M	$24.95M
YoY Change	309.17%	-83.78%	-79.25%
Cash & Equivalents	$28.23M	$4.156M	$24.95M
Short-Term Investments
Other Short-Term Assets	$2.125M	$8.335M	$9.181M
YoY Change	-77.63%	-30.61%	-12.96%
Inventory	$7.931M	$9.457M	$13.64M
Prepaid Expenses
Receivables	$4.013M	$3.339M
Other Receivables	$2.658M	$0.00
Total Short-Term Assets	$50.54M	$25.29M	$47.77M
YoY Change	61.29%	-50.74%	-63.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$42.75M	$43.25M	$94.03M
YoY Change	-54.94%	-54.82%	0.23%
Goodwill			$965.0K
YoY Change
Intangibles	$120.0K	$120.0K	$9.743M
YoY Change	-98.8%	-98.83%	8019.17%
Long-Term Investments
YoY Change
Other Assets	$951.0K	$961.0K	$1.129M
YoY Change	-9.51%	229.11%	194.01%
Total Long-Term Assets	$44.45M	$45.02M	$106.7M
YoY Change	-58.83%	-58.47%	12.41%
TOTAL ASSETS
Total Short-Term Assets	$50.54M	$25.29M	$47.77M
Total Long-Term Assets	$44.45M	$45.02M	$106.7M
Total Assets	$94.99M	$70.31M	$154.5M
YoY Change	-31.8%	-55.99%	-31.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.935M	$10.41M	$3.782M
YoY Change	-49.54%	35.62%	-53.12%
Accrued Expenses	$8.426M	$8.817M	$12.75M
YoY Change	-14.89%	-18.13%	26.11%
Deferred Revenue			$2.980M
YoY Change			-8.95%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.820M	$2.820M	$2.350M
YoY Change
Total Short-Term Liabilities	$15.18M	$22.04M	$18.88M
YoY Change	-14.39%	19.53%	3.87%
LONG-TERM LIABILITIES
Long-Term Debt	$5.172M	$5.668M	$6.561M
YoY Change
Other Long-Term Liabilities	$425.0K	$493.0K	$23.49M
YoY Change	-39.29%	-40.67%	7060.67%
Total Long-Term Liabilities	$5.172M	$5.668M	$6.561M
YoY Change	638.86%	582.07%	1900.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.18M	$22.04M	$18.88M
Total Long-Term Liabilities	$5.172M	$5.668M	$6.561M
Total Liabilities	$20.78M	$28.20M	$48.93M
YoY Change	12.62%	46.34%	164.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$708.6M	-$694.4M	-$600.7M
YoY Change	23.59%	27.32%	27.79%
Common Stock	$783.0M	$736.7M	$706.4M
YoY Change	12.77%	7.39%	4.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$74.21M	$42.10M	$105.5M
YoY Change
Total Liabilities & Shareholders Equity	$94.99M	$70.31M	$154.5M
YoY Change	-31.8%	-55.99%	-31.56%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q4
OPERATING ACTIVITIES
Net Income	-$14.21M	-$78.78M	-$27.32M
YoY Change	-49.19%	177.81%	-19.84%
Depreciation, Depletion And Amortization	$510.0K	$1.205M	$1.261M
YoY Change	-58.2%	33.89%	50.84%
Cash From Operating Activities	-$18.80M	-$9.919M	-$22.34M
YoY Change	-19.59%	-57.55%	0.19%
INVESTING ACTIVITIES
Capital Expenditures	$9.000K	$0.00	$435.0K
YoY Change	-99.51%	-100.0%	-90.69%
Acquisitions
YoY Change
Other Investing Activities			$5.000K
YoY Change
Cash From Investing Activities	-$9.000K	$0.00	-$430.0K
YoY Change	-98.9%	-100.0%	-90.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	42.91M	7.025M	40.72M
YoY Change	584.29%	582.7%	463.25%
NET CHANGE
Cash From Operating Activities	-18.80M	-9.919M	-22.34M
Cash From Investing Activities	-9.000K	0.000	-430.0K
Cash From Financing Activities	42.91M	7.025M	40.72M
Net Change In Cash	24.10M	-2.894M	17.94M
YoY Change	-234.38%	-93.76%	-190.89%
FREE CASH FLOW
Cash From Operating Activities	-$18.80M	-$9.919M	-$22.34M
Capital Expenditures	$9.000K	$0.00	$435.0K
Free Cash Flow	-$18.81M	-$9.919M	-$22.78M
YoY Change	-25.36%	-60.66%	-15.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-78776000	usd
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-19.28
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2023Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2024Q1	tnxp	Issuance Of Common Stock Upon Exercise Of Prefunded Warrants IssuanceOfCommonStockUponExerciseOfPrefundedWarrants		usd
CY2024Q2	tnxp	Issuance Of Common Stock Upon Exercise Of Prefunded Warrants IssuanceOfCommonStockUponExerciseOfPrefundedWarrants		usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Inventory Write Down InventoryWriteDown		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-694373000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4156000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	902000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	238000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	476000	usd
	us-gaap	Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2024#CostsAndExpenses
CY2024Q2	us-gaap	Goodwill Goodwill		usd
CY2023Q4	tnxp	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment		usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	692000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	770000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	493000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	277000	usd
CY2023Q4	tnxp	Preferred Stock Shares Designated PreferredStockSharesDesignated	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9832587	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9832587	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2077088	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2077088	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2074	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	706412000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-600658000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-232000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	105525000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	154457000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48487000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14417000	usd
CY2024Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	58957000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	58957000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	62904000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-62904000	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	855000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6150000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-605000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	646000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1198000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1543000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28356000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-93715000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-61361000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-19.28
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4085132	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4085132	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-78776000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-28356000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-93715000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-61361000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-45000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-78779000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28357000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-93726000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61406000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	105525000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	15850000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	23000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1692000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-14939000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	108143000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1704000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10730000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-9977000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	10832000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1154000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-78776000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	42103000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	207182000	usd
CY2023Q1	tnxp	Stock Repurchased During Period Transactional Expenses StockRepurchasedDuringPeriodTransactionalExpenses	334000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	13965000	usd
CY2023Q1	tnxp	Stock Issued During Period Value New Issues1 StockIssuedDuringPeriodValueNewIssues1	441000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	101000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1995000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	29000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	2794000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-44000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-33005000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	165427000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	36000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1029000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1029000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	2364000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-28356000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	140463000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-93715000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-61361000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2415000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1814000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	58957000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6150000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	1738000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	431000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2846000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5158000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3339000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2444000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1011000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-268000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	6703000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-571000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	7000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-833000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1593000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27494000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-56278000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	22174000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	108000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5644000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-108000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27818000	usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	3000000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	13965000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	23000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	29000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	940000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1704000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	137000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10730000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3465000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6813000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-10471000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-43000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20792000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-94610000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25850000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120470000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5058000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25860000	usd
	us-gaap	Interest Paid Net InterestPaidNet	653000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	106000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1164000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_803_eus-gaap--NatureOfOperations_zUk8AFIPC6jj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_820_zp3odvl2i1Nl">BUSINESS</span></b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tonix Pharmaceuticals Holding Corp., through its wholly owned subsidiary Tonix Pharmaceuticals, Inc. (“Tonix Sub”), is a fully-integrated biopharmaceutical company focused on developing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix aims to transform therapies for pain management and modernize solutions for public health challenges. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tonix’s development portfolio is focused on central nervous system (“CNS”) disorders. Tonix’s priority is to submit a New Drug Application (“NDA”) to the FDA in the second half of 2024 for TNX-102 SL for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for fibromyalgia. TNX-102 SL is also expected to be tested by the University of North Carolina under a physician IND for Acute Stress Reaction in a trial funded by the U.S. Department of Defense (DoD), Congressionally Directed Medical Research Program, or CDMRP for approximately $3 million. Tonix’s CNS portfolio also includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, in Phase 2 development that is funded by the U.S. National Institute of Drug Abuse or NIDA. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix is developing a broad-spectrum antiviral termed TNX-4200 under a contract for up to $34 million from the DoD Defense Threat Reduction Agency. Tonix’s development candidates are investigational drugs or biologics and are not approved for any indication. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial statements include the accounts of Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiaries, Tonix Sub, Krele LLC, Tonix Pharmaceuticals (Canada), Inc., Tonix Medicines, Inc., Jenner Institute LLC, Tonix R&D Center LLC, Tonix Pharma Holdings Limited and Tonix Pharma Limited (collectively, the “Company” or “Tonix”). All intercompany balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Going Concern</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has suffered recurring losses from operations and negative cash flows from operating activities. At June 30, 2024, the Company had working capital of approximately $<span id="xdx_904_ecustom--WorkingCapital_iI_pn5n6_c20240630_zupxe0VUo3xi" title="Working capital">3.2</span> million. At June 30, 2024, the Company had an accumulated deficit of approximately $<span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn3n3_dxL_c20240630_z0WktMGfErNa" title="Accumulated deficit::XDX::-694373"><span style="-sec-ix-hidden: xdx2ixbrl0635">694.4</span></span> million. The Company held cash and cash equivalents of approximately $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dxL_c20240630_zIPfvmnZay8c" title="Cash and cash equivalents::XDX::4156"><span style="-sec-ix-hidden: xdx2ixbrl0637">4.2</span></span> million as of June 30, 2024. During the fourth quarter of 2023, the Company engaged CBRE, an international real estate brokerage firm, to potentially find a strategic partner for, or buyer of, its Advanced Development Center in North Dartmouth, Massachusetts (“ADC”), to align with the Company’s current business objectives and priorities. As of June 30, 2024, the Company does not have a commitment in place to sell the ADC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that its cash resources at June 30, 2024 and the gross proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240701__20240816__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZgv5bX1Zlt" title="Proceeds from equity offerings">4.4</span> million that it raised from an equity offering in the third quarter of 2024 (See Note 18), will not meet its operating and capital expenditure requirements through the third quarter of 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company continues to face significant challenges and uncertainties and must obtain additional funding through public and private financing and collaborative arrangements with strategic partners to increase the funds available to fund operations. However, the Company may not be able to raise capital on terms acceptable to the Company, or at all. Without additional funds, it may be forced to delay, scale back or eliminate some or all of its research and development activities or other operations, and potentially delay product development in an effort to maintain sufficient funds to continue operations. If any of these events occurs, the Company’s ability to achieve development and commercialization goals will be adversely affected and the Company may be forced to cease operations. Moreover, the Company may default under the terms of its existing indebtedness. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </span></p>
CY2024Q2	tnxp	Working Capital WorkingCapital	3200000	usd
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-32
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zOcdODmoUSId" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Risks and uncertainties</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s primary efforts are devoted to conducting research and development of innovative pharmaceutical and biological products to address public health challenges. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. Further, the Company now has commercial products available for sale, and generates revenue from the sale of its Zembrace SymTouch and Tosymra products, with no assurance that the Company will be able to generate sufficient cash flow to fund operations from its commercial products or products in development if and when approved. In addition, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zsfepZxr4mmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include, but are not limited to, impairments, provisions for product returns, coupons, rebates, chargebacks, discounts, allowances, inventory realization, the assumptions used in the fair value of stock-based compensation and other equity instruments, the percent of completion of research and development contracts, fair value estimates for assets acquired in business combinations, and assessment of useful lives of acquired intangible assets. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	24000	usd
CY2023Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	19200000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	243000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4156000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25617000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	902000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	243000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5058000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25860000	usd
CY2024Q2	us-gaap	Inventory Write Down InventoryWriteDown	1700000	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	900000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	900000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1900000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1800000	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	48800000	usd
CY2024Q2	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	48800000	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	9200000	usd
CY2024Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	9200000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	965000	usd
CY2024Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	965000	usd
	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	30 to 90 days
	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	500000	usd
CY2024Q2	us-gaap	Government Assistance Amount Cumulative Current GovernmentAssistanceAmountCumulativeCurrent	300000	usd
	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	1900000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10846160	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	43542	shares
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3351000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3611000	usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1953000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2539000	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4153000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7489000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	9457000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	13639000	usd
CY2024Q2	us-gaap	Inventory Write Down InventoryWriteDown	1700000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46337000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	99390000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3090000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5362000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43247000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	94028000	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	48800000	usd
CY2024Q2	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	48800000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	965000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	965000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	965000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	10100000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	10100000	usd
CY2024Q2	tnxp	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	9147000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	953000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	477000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9623000	usd
CY2024Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	120000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	120000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9743000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	238000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	476000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	10060000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	11000000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2820000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2350000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	7240000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8650000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1572000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2089000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5668000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6561000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1410000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2820000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	5830000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	10060000	usd
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-32
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95543805	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2985924	shares
CY2024Q2	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	245205	shares
CY2024Q2	tnxp	Minimum Bid Requirement Per Share MinimumBidRequirementPerShare	1.00
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2208000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4690000	usd
CY2024Q2	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	4300000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	43245	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	50542.10
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	288934	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.19
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	21382	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	42044.88
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	310797	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4151.95
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y5M8D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	22609	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	51345.40
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.16
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	87.36
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	128.32
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0423	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0533	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0342	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0402	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.1189	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.3779	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.2126	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.4272	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10535363	shares
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	153000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	299000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	142000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	139000	usd
CY2024Q2	tnxp	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	108000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	841000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	71000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	770000	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	148000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	289000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y5M4D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M7D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0471	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0455	pure
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001999371-24-010281-index-headers.html	Edgar Link	pending
0001999371-24-010281-index.html	Edgar Link	pending
0001999371-24-010281.txt	Edgar Link	pending
0001999371-24-010281-xbrl.zip	Edgar Link	pending
ex31-01.htm	Edgar Link	pending
ex31-02.htm	Edgar Link	pending
ex32-01.htm	Edgar Link	pending
ex32-02.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tnxp-10q_063024.htm	Edgar Link	pending
tnxp-20240630.xsd	Edgar Link	pending
tnxp-20240630_cal.xml	Edgar Link	unprocessable
tnxp-20240630_def.xml	Edgar Link	unprocessable
tnxp-20240630_lab.xml	Edgar Link	unprocessable
tnxp-20240630_pre.xml	Edgar Link	unprocessable
tnxp-10q_063024_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TNXP
Tonix Pharmaceuticals Holding Corp. Stock $tnxp

2024 Q3 Form 10-Q Financial Statement

#000199937124010281 Filed on August 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNXP Tonix Pharmaceuticals Holding Corp. Stock $tnxp

2024 Q3 Form 10-Q Financial Statement

#000199937124010281 Filed on August 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNXP
Tonix Pharmaceuticals Holding Corp. Stock $tnxp